UBC Acquires Gigamoto Technology Partners
The recent acquisition of Gigamoto Technology Partners (W. Conshohocken, PA) expands United BioSource Corporation's (Bethesda, MD) leadership in drug safety, the company says. The purchase is UBC's second of the year and provides the company with several risk management programs, including the largest and longest running FDA-mandated program: iPLEDGE, an interactive computer-based distribution center that monitors pregnancy in women on Accutane.
“Managing drug safety for increasingly complex drugs and biologicals requires world class scientific expertise, strong operations, and demands state of the art technology,” said Ethan Leder, Chief Executive Officer of United Biosource. “The acquisition of Gigamoto enhances and accelerates our technology platform to include more top-notch FDA approved technology solutions for complex post-approval programs."
The full press release is available here.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
